Key facts
- This page summarizes Amit Kumar's Form 4 filing for Anixa Biosciences Inc (ANIX).
- 3 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 02 Jun 2021, 17:00.
Amit Kumar - 31 May 2021 Form 4 Insider Report for Anixa Biosciences Inc (ANIX)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- ANIX
- Reported as of
- 31 May 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Jun 2021, 17:00:15 UTC
- Next SEC filing
- 20 Jul 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Amit Kumar
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Amit Kumar filed Form 4 for Anixa Biosciences Inc (ANIX) on 02 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ANIX
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +2,000,000
- Change %
- Price
- $0.000000
- Shares after
- 2,000,000
- Date
- 01 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,000,000
- Exercise price
- $4.02
- Footnotes
- F1, F2
ANIX
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +500,000
- Change %
- Price
- $0.000000
- Shares after
- 500,000
- Date
- 01 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 500,000
- Exercise price
- $4.02
- Footnotes
- F1, F3
ANIX
transaction
Derivative
Restricted Stock Award
Disposed to Issuer
- Transaction value
- $0
- Shares
- -1,500,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 31 May 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,500,000
- Exercise price
- $0.000000
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan.
Footnote F2
The options vest and become exercisable as follows: (i) 500,000 shares vest if during any 5 trading day period, the average closing price of the issuer's common stock is at least $5.00, (ii) 500,000 shares vest if during any 5 trading day period, the average closing price of the issuer's common stock is at least $6.00, (iii) 500,000 shares vest if during any 5 trading day period, the average closing price of the issuer's common stock is at least $7.00, and (iv) 500,000 shares vest if during any 5 trading day period, the average closing price of the issuer's common stock is at least $8.00.
Footnote F3
The options vest and become exercisable in thirty-six (36) equal monthly installments beginning June 30, 2021.
Footnote F4
The vesting requirements were not met and the restricted stock award expired on May 31, 2021.